Pirola Giacomo M, Gubbiotti Marilena, Rubilotta Emanuele, Castellani Daniele, Trabacchin Nicolò, Tafuri Alessandro, Princiotta Alessandro, Martorana Eugenio, Annino Filippo, Antonelli Alessandro
Department of Urology, Usl Toscana Sud Est, San Donato Hospital, Arezzo, Italy.
Department of Urology, A.O.U.I. University of Verona, Verona, Italy.
Prostate Int. 2022 Mar;10(1):34-37. doi: 10.1016/j.prnil.2021.11.001. Epub 2021 Dec 7.
This study aimed to assess the incidence of urinary tract infections (UTIs) after transperineal prostate biopsy (TP-PB) comparing patients who underwent antibiotic prophylaxis (AP) with patients who had no prophylaxis.
This prospective, double-center trial was conducted between August and December 2020. Patient candidates to PB were included with 1:1 allocation to case (Group A-no AP) and control group (Group B-standard AP). All TP-PBs were performed in an outpatient setting under local anesthesia. Data collected 2 weeks after the procedure included incidence of UTIs or bacteriuria, evaluated with a urine culture (UC), main symptoms, and complications related to TP-PBs.
A total of 200 patients were included (100 patients in each group). The mean age was 66.2 ± 7.7 in Group A and 67.4 ± 8 years in Group B ( = 0.134). Mean prostate volume was 65.5 ± 26.7 vs. 51 ± 24.6 cc ( < 0.001), number of biopsy cores was 17.8 ± 2.4 vs. 14.9 ± 0.8 ( < 0.001), and PSA value was 15.9 ± 28.1 vs. 13.3 ± 22.3 ng/ml ( = 0.017). Overall PCa detection rate was 55% vs. 59% ( = 0.567). Postoperative UTI occurred in one patient in Group A vs. zero in Group B. Asymptomatic bacteriuria was present in 3 vs. 5 patients ( = 0.470) and was not treated with antibiotics. Postoperative hematuria was observed in 13 patients vs. 29 ( < 0.05), and acute urinary retention was observed in one patient in each group.
The incidence of bacteriuria and UTIs in TP-PBs is not related to AP. Therefore, AP could be discontinued in TP-PB candidates without the risk of increasing UTI-related complications.
本研究旨在评估经会阴前列腺穿刺活检(TP-PB)后尿路感染(UTI)的发生率,比较接受抗生素预防(AP)的患者与未接受预防的患者。
这项前瞻性、双中心试验于2020年8月至12月进行。符合前列腺穿刺活检条件的患者按1:1比例分配至病例组(A组 - 未接受AP)和对照组(B组 - 标准AP)。所有TP-PB均在门诊局部麻醉下进行。术后2周收集的数据包括UTI或菌尿症的发生率(通过尿培养[UC]评估)、主要症状以及与TP-PB相关的并发症。
共纳入200例患者(每组100例)。A组平均年龄为66.2±7.7岁,B组为67.4±8岁(P = 0.134)。平均前列腺体积分别为65.5±26.7 vs. 51±24.6立方厘米(P < 0.001),穿刺针数分别为17.8±2.4 vs. 14.9±0.8(P < 0.001),前列腺特异性抗原(PSA)值分别为15.9±28.1 vs. 13.3±22.3纳克/毫升(P = 0.017)。总体前列腺癌(PCa)检出率分别为55% vs. 59%(P = 0.567)。A组有1例患者发生术后UTI,B组为0例。无症状菌尿症在A组有3例,B组有5例(P = 0.470),且未使用抗生素治疗。术后血尿在A组观察到13例,B组观察到29例(P < 0.05),每组各有1例患者发生急性尿潴留。
TP-PB中菌尿症和UTI的发生率与AP无关。因此,对于TP-PB候选患者可以停用AP,而不会增加与UTI相关并发症的风险。